List view / Grid view
3 June 2016 | By Victoria White, Digital Content Producer
Shire and Baxalta have combined businesses, creating a leading global company focused on rare diseases and other highly specialised conditions...
4 March 2016 | By Victoria White
BAX 826 is a next-generation rFVIII treatment based on the full length Advate that uses proprietary polysialic acid technology to extend its circulating half-life...
2 March 2016 | By Victoria White
Adynovi is an extended circulating half-life recombinant Factor VIII treatment, for paediatric, adolescent and adult patients with haemophilia A...
19 January 2016 | By Victoria White
With this authorisation, Oncaspar will provide an important treatment option for more European patients with this rapidly progressing cancer of the white blood cells...
11 January 2016 | By Victoria White
The combination of Shire and Baxalta will create the number one rare diseases platform in revenue and pipeline depth...
21 December 2015 | By Victoria White
The study enrolled 73 previously-treated patients with severe haemophilia A younger than 12 years of age and assessed the treatment's haemostatic efficacy in prophylaxis and treatment of bleeding episodes...
9 December 2015 | By Victoria White
Vonvendi [von Willebrand factor (Recombinant)] is the first and only recombinant treatment for adults living with von Willebrand Disease (VWD)...
20 November 2015 | By Victoria White
Baxalta expects to begin treating participants in the open-label, dose-finding study by early 2016...
16 November 2015 | By Victoria White
Adynovate has been shown to reduce the number of bleeding episodes during routine care...
13 November 2015 | By Victoria White
Obizur is the first recombinant porcine sequence FVIII treatment available in Europe to treat acquired haemophilia A...
10 November 2015 | By Victoria White
CHS-0214 met its primary endpoints in a Phase 3 study in patients with moderate-to-severe chronic plaque psoriasis...
27 October 2015 | By Victoria White
The start-up of this study resulted in $62.5M of milestone payments to Merrimack from Baxalta...
4 August 2015 | By Victoria White
Shire made a proposal to Baxalta on 10 July 2015 to combine the companies in an all-stock transaction worth approximately $30.6 billion...
28 July 2015 | By Victoria White
The CHMP has adopted a positive opinion for the marketing authorisation of Obizur for the treatment of bleeding episodes in patients with haemophilia...
